Development of Erythema Nodosum After Olaparib Treatment in a Patient With Recurrent Breast Cancer and BRCA2 Mutation: A Case Report

BRCA1 and 2 mutations are known to be associated with breast cancer, and olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, has been shown to be effective in cells carrying these mutations in some studies. Erythema nodosum (EN), which is one adverse event of olaparib and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Masayuki, Fujii, Kimihito, Banno, Hirona, Ito, Yukie, Nakano, Shogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484634/
https://www.ncbi.nlm.nih.gov/pubmed/37692183
http://dx.doi.org/10.7759/cureus.44864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484634/
https://www.ncbi.nlm.nih.gov/pubmed/37692183
http://dx.doi.org/10.7759/cureus.44864

Ejemplares similares